Tillbaka till portföljen
Aprovix
Aprovix logo

Aprovix

MedTech

Clinically validated HPV self-sampling for cervical cancer prevention.

Besök webbplats
Self-TestingCervical CancerWomen's Health

Investerat

2013

Grundat

2001

Huvudkontor

Solna, Sweden

Sektor

MedTech


Om

Aprovix develops the Qvintip self-sampling device for at-home HPV detection, enabling women to screen for cervical cancer privately and conveniently with clinic-equivalent accuracy. Validated in 25 clinical studies involving over 90,000 women, the ISO 13485 certified device aligns with WHO recommendations for HPV-based screening.